健择低剂量延长时间输注治疗恶性肿瘤的初步观察  

Study on the efficacy and safety of prolonged infusions of low-dose gemcitabine in treatment of advanced carcinoma

作　　者：王丽[1] 陆建伟[1] 孙小峰[1] 郑秀立[1] 

机构地区：[1]江苏省肿瘤防治研究所内科,南京210009

出　　处：《临床肿瘤学杂志》2004年第3期256-257,共2页Chinese Clinical Oncology

摘　　要：目的 :初步探索健择低剂量延长时间输注治疗恶性肿瘤的疗效及其安全性。方法 :健择 2 0 0mg持续静脉输注 2 2小时 ,第 1、8天 ,或 4 0 0mg持续静脉输注 6小时 ,第 1、8天 ,2 1天为 1周期 ,其它化疗药物按常规剂量及方法使用。完成 2周期者作疗效评定。结果 :全组 7例共完成 11周期化疗 ,4例可作疗效评定 ,其中 2例PR ,2例SD ,有效率为 5 0 %。主要毒副反应为骨髓抑制。结论 :初步结果显示 ,健择低剂量延长时间输注治疗恶性肿瘤具有一定的可行性和有效性。Objective:To observe the efficacy and safety of prolonged infusions of low-dose gemcitabine in treatment of advanced carcinoma.Methods:7 patients were enrolled this study. Gemcitabine 200 mg was given by infusion for 22 hours or 400 mg for 6 hours(d1,8 every 21 days).The administration of other drugs was used regularly. The immediate responses were assessed in cases who completed two cycles of chemotherapy.Results:Among these patients,7 cases received 11 cycles of chemo-therapy. 4 patients received 2 cycles were assessable for determination of response, the overall response rate was 50% with 2 PR. The main toxicity was myelosupression.Conclusion:The elementory result showed that the prolonged infusion of low-dose gemcitabine have a certain feasibility and usefulness for patients with advanced carcinoma.

关 键 词：低剂量 治疗 恶性肿瘤 安全性 毒副反应 静脉输注 吉西他滨 

分 类 号：R730.53[医药卫生—肿瘤]